| TOP STORY |
Rare Disorder Found to Have a Common Form
A hereditary autoimmune disease that was thought to be exceedingly rare may have a less severe form that affects one in 1,000 people or even more. The results suggest that a number of different autoimmune diseases and syndromes may be tied to mutations in a single gene. [Press release from Weizmann Institute of Science discussing online publication in Immunity]
Press Release | Full Article
|
Graphical Abstract
|
|
| INDUSTRY NEWS |
Adimab Establishes New Collaboration with Kite Pharma for the Discovery of Antibodies for T-Cell Therapies
Adimab, LLC announced a new collaboration with Kite Pharma, Inc. Under the terms of the agreement, Adimab will use its proprietary platform to generate IgGs against multiple targets selected by Kite. [Adimab, LLC] Press Release
Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
Kite Pharma, Inc. and bluebird bio, Inc. announced that they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor (TCR) product candidates directed against the human papillomavirus (HPV) type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies. [Kite Pharma, Inc.] Press Release
TGen and Mayo Clinic Help Launch National Clinical Trials to Combat Advanced Skin Cancer
The Translational Genomics Research Institute (TGen) and Mayo Clinic are helping launch a national clinical trial that will apply the latest in precision medicine to treat advanced melanoma skin cancer. [Translational Genomics Research Institute] Press Release
Vaxil’s Lead Product ImMucin Has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma
Vaxil Bio reported that its lead product, ImMucin, has been granted an “orphan drug” designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma. [Vaxil BioTherapeutics Ltd.] Press Release
ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus
The Alliance for Children’s Therapeutics (ACT) marked its first year anniversary with an encouraging status report on early research efforts using Kineta’s lead drug dalazatide, formerly ShK-186, for children and teens with lupus nephritis. [Kineta Inc. (Business Wire)] Press Release
SITC Announces Cancer Immunotherapy Clinical Fellowship Award Recipient
The Society for Immunotherapy of Cancer (SITC) announced Jonathan Peled, MD, PhD, of Memorial Sloan Kettering Cancer Center, as the recipient of the SITC-Merck Cancer Immunotherapy Clinical Fellowship Award. This award supports the development of the next generation of immunotherapy experts through dedicated funding of novel research. [Society for Immunotherapy of Cancer]
Press Release
|
| EVENTS |
NEW Cancer Vaccines
September 16-17, 2015 London, United Kingdom
Visit our events page to see a complete list of events in the human immunology community.
|
|